Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
|ClinicalTrials.gov Identifier: NCT00006097|
Recruitment Status : Completed
First Posted : May 4, 2004
Last Update Posted : September 22, 2010
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Drug: CC-1088||Phase 1 Phase 2|
OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients.
OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial|
|Study Start Date :||August 1999|
|Primary Completion Date :||July 2005|
|Study Completion Date :||July 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006097
|United States, Massachusetts|
|Boston Medical Center|
|Boston, Massachusetts, United States, 02118|
|Study Chair:||Timothy J. Ernst, MD||Boston Medical Center|